20 articles found
NIDA awarded Newleos up to $15.5 million over five years to test its TAAR1 partial agonist in cocaine use disorder; FDA granted Fast Track in alcohol use disorder.
An October Annenberg survey found 58% know regular drinking raises cancer risk, up 5 points since February, though 42% still doubt or misunderstand the link.
Four years of Utah crash data show the nation's only 0.05% blood alcohol limit was followed by a 9% drop in alcohol-involved crashes, IIHS reports.
A CMAJ study of 2.2 million Ontario women finds substance-related emergency visits climbing almost 5% annually among mothers, and 8% among those under 25.
A study of 4,232 hospitalizations found new alcohol use disorder prescriptions at discharge in just 11%, and the odds tracked hospital structure more than patient traits.
Ashley Addiction Treatment opened a research-only building in Havre de Grace, Maryland, where it will run a Johns Hopkins trial pairing GLP-1 drugs with naltrexone.
A year of monthly smartphone tasks in people with alcohol use disorder found that spikes in risk-taking predicted heavier drinking the next month, not the reverse.
A $13.3 million Arnold Ventures grant funds a Pittsburgh randomized trial of weekly semaglutide for alcohol and opioid use disorder, launching in early 2027.
A NIAAA-funded study finds only 58.5% of alcohol treatment facilities offer women-specific care and 4.6% provide childcare, even in states with the highest need.
What a month without alcohol does to sleep, mood and health, who should not quit cold turkey, and what it means if 31 days feels harder than expected.
Massachusetts health officials now say even moderate drinking can raise the risk of cancer, high blood pressure and heart disease, going further than federal advice.
UC San Diego receives a five-year, $12.6 million NIDA award to launch the Polysubstance Addiction Research Center studying cocaine, opioids and alcohol.
FDA clears IND application for ANS-858, a first-in-class ALDH2 inhibitor targeting pathological craving in alcohol and substance use disorders, clearing path to Phase 1 trials.
The VA's CRAVE trial will enroll more than 600 veterans at 18 medical centers to test whether weekly semaglutide injections can treat alcohol use disorder.
Phase 2 RECLAIM trial shows pemvidutide significantly reduces heavy drinking days in alcohol use disorder patients, offering hope for 28 million Americans.
Landmark BMJ study of 600,000+ veterans finds GLP-1 medications like Ozempic and Wegovy associated with 14-25% lower risk of developing substance use disorders, including alcohol, opioids, and stimulants.
Washington University study of 600,000 veterans finds GLP-1 medications like Ozempic and Wegovy associated with reduced risks of substance use disorders and fewer overdoses across alcohol, opioids, nicotine, and other drugs.
The Department of Veterans Affairs begins first government-sponsored study of MDMA-assisted therapy, enrolling 80 veterans in groundbreaking research on psychedelic treatment for co-occurring conditions.
Clinical trial shows semaglutide plus cognitive behavioral therapy significantly reduces alcohol consumption, offering new hope for treating alcohol use disorder with existing medications.
New BMJ research finds semaglutide and similar medications associated with 14% reduced risk of developing substance use disorders and 50% fewer deaths among veterans already in treatment.